Breast Cancer Research and Treatment

, Volume 102, Issue 3, pp 253–261 | Cite as

MMP-2 and MMP-9 activity is regulated by estradiol and tamoxifen in cultured human breast cancer cells

  • Ulrika W Nilsson
  • Stina Garvin
  • Charlotta DabrosinEmail author
Preclinical Study


Sex steroids play a dominant role in breast carcinogenesis by still largely unknown mechanisms. Matrix metalloproteinases (MMPs) have been extensively studied in the context of matrix biology but it is not known if sex steroids affect MMPs in breast cancer. MMPs degrade extracellular matrix components enabling tumor cell invasion and metastasis, but may also regulate the bioavailability of a variety of biologically active molecules such as anti-angiogenic fragments, which may be beneficial for the host. This study shows that estradiol and tamoxifen regulate MMP-2 and MMP-9 as well as TIMP-1 and TIMP-2 in ER + PR + human breast cancer cells. The main finding was a significant effect of tamoxifen exposure, which increased intracellular and secreted protein levels whereas estradiol induced a significant decrease. The overall net effect of these alterations resulted in increased MMP-2/MMP-9 activity by tamoxifen treatment, which also significantly increased extracellular endostatin levels. We conclude that estradiol and tamoxifen have the ability to modulate MMP-2/MMP-9 activity, and endostatin levels in human breast cancer in vitro. The results suggest a possible role of MMP modulation associated with a generation of anti-angiogenic fragments in the therapeutic effect of tamoxifen in breast cancer.


Breast cancer Endostatin Estrogen Matrix metalloproteinases Tamoxifen Tissue inhibitors of matrix metalloproteinases MCF-7 cells 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.



This study was supported by grants from the Swedish Cancer Society, Linköping University Hospital, and Gunnar Nilsson’s Cancer Foundation.


  1. 1.
    Gloeckler Ries LA, Reichman ME, Lewis DR, Hankey BF, Edwards BK (2003) Cancer survival and incidence from the Surveillance, Epidemiology, and End Results (SEER) program. Oncologist 8:541–552PubMedCrossRefGoogle Scholar
  2. 2.
    Woodhouse EC, Chuaqui RF, Liotta LA (1997) General mechanisms of metastasis. Cancer 80:1529–1537PubMedCrossRefGoogle Scholar
  3. 3.
    Duffy MJ, Maguire TM, Hill A, McDermott E, O’Higgins N (2000) Metalloproteinases: role in breast carcinogenesis, invasion and metastasis. Breast Cancer Res 2:252–257PubMedCrossRefGoogle Scholar
  4. 4.
    Chambers AF, Matrisian LM (1997) Changing views of the role of matrix metalloproteinases in metastasis. J Natl Cancer Inst 89:1260–1270PubMedCrossRefGoogle Scholar
  5. 5.
    Stetler-Stevenson WG, Yu AE (2001) Proteases in invasion:␣matrix metalloproteinases. Semin Cancer Biol 11:143–153PubMedCrossRefGoogle Scholar
  6. 6.
    Kleiner DE, Stetler-Stevenson WG (1999) Matrix metalloproteinases and metastasis. Cancer Chemother Pharmacol 43 Suppl:S42–51.:S42–S51Google Scholar
  7. 7.
    Brooks PC, Stromblad S, Sanders LC, von Schalscha TL, Aimes RT, Stetler-Stevenson WG, Quigley JP, Cheresh DA (1996) Localization of matrix metalloproteinase MMP-2 to the surface of invasive cells by interaction with integrin alpha v beta 3. Cell 85:683–693PubMedCrossRefGoogle Scholar
  8. 8.
    Liotta LA, Stetler-Stevenson WG (1990) Metalloproteinases and cancer invasion. Semin Cancer Biol 1:99–106PubMedGoogle Scholar
  9. 9.
    Nakopoulou L, Tsirmpa I, Alexandrou P, Louvrou A, Ampela C, Markaki S, Davaris PS (2003) MMP-2 protein in invasive breast cancer and the impact of MMP-2/TIMP-2 phenotype on overall survival. Breast Cancer Res Treat 77:145–155PubMedCrossRefGoogle Scholar
  10. 10.
    Stetler-Stevenson WG, Liotta LA, Brown PD (1992) Role of type IV collagenases in human breast cancer. Cancer Treat Res 61:21–41PubMedGoogle Scholar
  11. 11.
    Young TN, Rodriguez GC, Rinehart AR, Bast J, Pizzo SV, Stack MS (1996) Characterization of gelatinases linked to extracellular matrix invasion in ovarian adenocarcinoma: purification of matrix metalloproteinase 2. Gynecol Oncol 62:89–99PubMedCrossRefGoogle Scholar
  12. 12.
    Mott JD, Werb Z (2004) Regulation of matrix biology by matrix metalloproteinases. Curr Opin Cell Biol 16:558–564PubMedCrossRefGoogle Scholar
  13. 13.
    Sottile J (2004) Regulation of angiogenesis by extracellular matrix. Biochimica et Biophysica Acta (BBA)—Reviews on Cancer 1654:13–22CrossRefGoogle Scholar
  14. 14.
    Bergers G, Brekken R, McMahon G, Vu TH, Itoh T, Tamaki K, Tanzawa K, Thorpe P, Itohara S, Werb Z, Hanahan D (2000) Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol 2:737–744PubMedCrossRefGoogle Scholar
  15. 15.
    Cornelius LA, Nehring LC, Harding E, Bolanowski M, Welgus HG, Kobayashi DK, Pierce RA, Shapiro SD (1998) Matrix metalloproteinases generate angiostatin: effects on neovascularization. J Immunol 161:6845–6852PubMedGoogle Scholar
  16. 16.
    Ferreras M, Felbor U, Lenhard T, Olsen BR, Delaisse JM (2000) Generation and degradation of human endostatin proteins by various proteinases. FEBS Letters 486:247–251PubMedCrossRefGoogle Scholar
  17. 17.
    Hamano Y, Zeisberg M, Sugimoto H, Lively JC, Maeshima Y, Yang C, Hynes RO, Werb Z, Sudhakar A, Kalluri R (2003) Physiological levels of tumstatin, a fragment of collagen IV alpha3 chain, are generated by MMP-9 proteolysis and suppress angiogenesis via alphaV beta3 integrin. Cancer Cell 3:589–601PubMedCrossRefGoogle Scholar
  18. 18.
    Pozzi A, Moberg PE, Miles LA, Wagner S, Soloway P, Gardner HA (2000) Elevated matrix metalloprotease and angiostatin levels in integrin alpha 1 knockout mice cause reduced tumor vascularization. Proc Natl Acad Sci USA 97:2202–2207PubMedCrossRefGoogle Scholar
  19. 19.
    Writing Group for the Women’s Health Initiative Investigators (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the women’s health initiative randomized controlled trial. JAMA 288:321–333CrossRefGoogle Scholar
  20. 20.
    Collaborative Group on Hormonal Factors in Breast Cancer (1997) Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet 350:1047–1059CrossRefGoogle Scholar
  21. 21.
    Hulboy DL, Rudolph LA, Matrisian LM (1997) Matrix metalloproteinases as mediators of reproductive function. Mol Hum Reprod 3:27–45PubMedCrossRefGoogle Scholar
  22. 22.
    Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2-[Delta][Delta]CT method. Methods 25:402–408PubMedCrossRefGoogle Scholar
  23. 23.
    Riley SC, Thomassen R, Bae SE, Leask R, Pedersen HG, Watson ED (2004) Matrix metalloproteinase-2 and -9 secretion by the equine ovary during follicular growth and prior to ovulation. Anim Reprod Sci 81:329–339PubMedCrossRefGoogle Scholar
  24. 24.
    Visse R, Nagase H (2003) Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res 92:827–839PubMedCrossRefGoogle Scholar
  25. 25.
    Nagase H, Woessner JF, Jr. (1999) Matrix metalloproteinases. J Biol Chem 274:21491–21494PubMedCrossRefGoogle Scholar
  26. 26.
    Bein K, Simons M (2000) Thrombospondin Type 1 repeats interact with matrix metalloproteinase 2. Regulation of metalloproteinase activity. J Biol Chem 275:32167–32173PubMedCrossRefGoogle Scholar
  27. 27.
    Rodriguez-Manzaneque JC, Lane TF, Ortega MA, Hynes RO, Lawler J, Iruela-Arispe ML (2001) Thrombospondin-1 suppresses spontaneous tumor growth and inhibits activation of matrix metalloproteinase-9 and mobilization of vascular endothelial growth factor. PNAS 98:12485–12490PubMedCrossRefGoogle Scholar
  28. 28.
    Sottrup-Jensen L, Birkedal-Hansen H (1989) Human fibroblast collagenase-alpha-macroglobulin interactions. Localization of cleavage sites in the bait regions of five mammalian alpha-macroglobulins. J Biol Chem 264:393–401PubMedGoogle Scholar
  29. 29.
    Hirvonen R, Talvensaari-Mattila A, Paakko P, Turpeenniemi-Hujanen T (2003) Matrix metalloproteinase-2 (MMP-2) in T(1–2)N0 breast carcinoma. Breast Cancer Res Treat 77:85–91PubMedCrossRefGoogle Scholar
  30. 30.
    Li HC, Cao DC, Liu Y, Hou YF, Wu J, Lu JS, Di GH, Liu G, Li FM, Ou ZL, Jie C, Shen ZZ, Shao ZM (2004) Prognostic value of matrix metalloproteinases (MMP-2 and MMP-9) in patients with lymph node-negative breast carcinoma. Breast Cancer Res Treat 88:75–85PubMedCrossRefGoogle Scholar
  31. 31.
    Pozzi A, LeVine WF, Gardner HA (2002) Low plasma levels of matrix metalloproteinase 9 permit increased tumor angiogenesis. Oncogene 21:272–281PubMedCrossRefGoogle Scholar
  32. 32.
    McCawley LJ, Matrisian LM (2001) Matrix metalloproteinases: they’re not just for matrix anymore. Curr Opin Cell Biol 13:534–540PubMedCrossRefGoogle Scholar
  33. 33.
    Chang C, Werb Z (2001) The many faces of metalloproteases: cell growth, invasion, angiogenesis and metastasis. Trends Cell Biol 11:S37–S43PubMedGoogle Scholar
  34. 34.
    Coussens LM, Werb Z (2002) Inflammation and cancer. Nature 420:860–867PubMedCrossRefGoogle Scholar
  35. 35.
    Lynch CC, Matrisian LM (2002) Matrix metalloproteinases in tumor-host cell communication. Differentiation 70:561–573PubMedCrossRefGoogle Scholar
  36. 36.
    Garvin S, Dabrosin C (2003) Tamoxifen inhibits secretion of vascular endothelial growth factor in breast cancer in vivo. Cancer Res 63:8742–8748PubMedGoogle Scholar
  37. 37.
    Abbas Abidi SM, Howard EW, Dmytryk JJ, Pento JT (1997) Differential influence of antiestrogens on the in vitro release of gelatinases (type IV collagenases) by invasive and non-invasive breast cancer cells. Clin Exp Metastasis 15:432–439PubMedCrossRefGoogle Scholar
  38. 38.
    Philips N, McFadden K (2004) Inhibition of transforming growth factor-beta and matrix metalloproteinases by estrogen and prolactin in breast cancer cells. Cancer Lett 206:63–68PubMedCrossRefGoogle Scholar
  39. 39.
    van den Brule FA, Engel J, Stetler-Stevenson WG, Liu FT, Sobel ME, Castronovo V (1992) Genes involved in tumor invasion and metastasis are differentially modulated by estradiol and progestin in human breast-cancer cells. Int J␣Cancer 52:653–657PubMedCrossRefGoogle Scholar
  40. 40.
    Dabrosin C, Margetts PJ, Gauldie J (2003) Estradiol increases extracellular levels of vascular endothelial growth factor in vivo in murine mammary cancer. Int J Cancer 107:535–540PubMedCrossRefGoogle Scholar
  41. 41.
    Dabrosin C (2003) Variability of vascular endothelial growth factor in normal human breast tissue in vivo during the menstrual cycle. J Clin Endocrinol Metab 88:2695–2698PubMedCrossRefGoogle Scholar
  42. 42.
    Dabrosin C, Palmer K, Muller WJ, Gauldie J (2003) Estradiol promotes growth and angiogenesis in polyoma middle T transgenic mouse mammary tumor explants. Breast Cancer Res Treat 78:1–6PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2006

Authors and Affiliations

  • Ulrika W Nilsson
    • 1
  • Stina Garvin
    • 1
  • Charlotta Dabrosin
    • 1
    Email author
  1. 1.Division of Gynecologic OncologyUniversity HospitalLinköpingSweden

Personalised recommendations